Boothe Investment Group Inc. acquired a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 435,939 shares of the biopharmaceutical company’s stock, valued at approximately $2,559,000. Lexicon Pharmaceuticals makes up 1.5% of Boothe Investment Group Inc.’s holdings, making the stock its 24th biggest position.
Other institutional investors also recently added to or reduced their stakes in the company. Steel Peak Wealth Management LLC bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $34,000. Victory Capital Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at about $42,000. XTX Markets LLC purchased a new stake in Lexicon Pharmaceuticals in the fourth quarter worth about $45,000. Aperio Group LLC bought a new position in Lexicon Pharmaceuticals during the 4th quarter worth about $50,000. Finally, Dimensional Fund Advisors LP purchased a new position in Lexicon Pharmaceuticals during the 4th quarter valued at about $57,000. 84.62% of the stock is owned by institutional investors.
In related news, VP James F. Tessmer sold 22,912 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $6.92, for a total transaction of $158,551.04. Following the completion of the sale, the vice president now owns 71,766 shares of the company’s stock, valued at $496,620.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.40% of the company’s stock.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, March 10th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.23. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.17 million. Lexicon Pharmaceuticals had a negative net margin of 320.44% and a negative return on equity of 164.96%. On average, equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.11 earnings per share for the current year.
LXRX has been the topic of a number of recent research reports. G.Research downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 15th. Wedbush downgraded Lexicon Pharmaceuticals from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $2.00 to $8.00 in a report on Friday, January 29th. JPMorgan Chase & Co. upgraded Lexicon Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $7.00 price objective for the company in a research note on Friday, January 29th. Smith Barney Citigroup lifted their target price on Lexicon Pharmaceuticals from $6.00 to $13.00 in a research note on Thursday, January 14th. Finally, Citigroup increased their price target on shares of Lexicon Pharmaceuticals from $6.00 to $13.00 in a research report on Friday, January 15th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $9.13.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.